121 related articles for article (PubMed ID: 36355053)
1. Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.
Groti Antonič K
Aging Male; 2022 Dec; 25(1):269-277. PubMed ID: 36355053
[TBL] [Abstract][Full Text] [Related]
2. Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.
Nguyen LT; Nguyen UDT; Nguyen TDT; Ho-Pham LT; Nguyen TV
Osteoporos Int; 2018 Dec; 29(12):2739-2744. PubMed ID: 30196375
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.
Colleluori G; Aguirre L; Napoli N; Qualls C; Villareal DT; Armamento-Villareal R
J Clin Endocrinol Metab; 2021 Jul; 106(8):e3058-e3068. PubMed ID: 33735389
[TBL] [Abstract][Full Text] [Related]
4. Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors - results from a randomized double-blind trial.
Jørgensen PL; Kreiberg M; Jørgensen N; Juul A; Oturai PS; Dehlendorff C; Lauritsen J; Wagner T; Rosenvilde J; Daugaard G; Medici CR; Jørgensen NR; Bandak M
Acta Oncol; 2023 Jul; 62(7):689-695. PubMed ID: 37151105
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
[TBL] [Abstract][Full Text] [Related]
6. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
7. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
Bønløkke SE; Rand MS; Haddock B; Arup S; Smith CD; Jensen JEB; Schwarz P; Hovind P; Oturai PS; Jensen LT; Møller S; Eiken P; Rubin KH; Hitz MF; Abrahamsen B; Jørgensen NR
Osteoporos Int; 2022 Oct; 33(10):2155-2164. PubMed ID: 35729342
[TBL] [Abstract][Full Text] [Related]
8. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
9. Bone Turnover Markers and Bone Mineral Density to Predict Osteoporotic Fractures in Older Women: A Retrospective Comparative Study.
Qu XL; Zheng B; Chen TY; Cao ZR; Qu B; Jiang T
Orthop Surg; 2020 Feb; 12(1):116-123. PubMed ID: 31880071
[TBL] [Abstract][Full Text] [Related]
10. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus.
Jiajue R; Jiang Y; Wang O; Li M; Xing X; Cui L; Yin J; Xu L; Xia W
Osteoporos Int; 2014 Aug; 25(8):1999-2005. PubMed ID: 24760246
[TBL] [Abstract][Full Text] [Related]
11. [PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS].
Ren H; Shen G; Jiang X; Liang D; Tang J; Cui J; Lin S; Zhuang H; Yang Z; Zhang S; Yao Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2015 Mar; 29(3):307-14. PubMed ID: 26455196
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
14. Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials.
Zibellini J; Seimon RV; Lee CM; Gibson AA; Hsu MS; Shapses SA; Nguyen TV; Sainsbury A
J Bone Miner Res; 2015 Dec; 30(12):2168-78. PubMed ID: 26012544
[TBL] [Abstract][Full Text] [Related]
15. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
16. The effect of short- and long-term growth hormone treatment on bone mineral density and bone metabolism of prepubertal children with idiopathic short stature: a 3-year study.
Lanes R; Gunczler P; Esaa S; Weisinger JR
Clin Endocrinol (Oxf); 2002 Dec; 57(6):725-30. PubMed ID: 12460321
[TBL] [Abstract][Full Text] [Related]
17. Alendronate for osteoporosis in men with androgen-repleted hypogonadism.
Shimon I; Eshed V; Doolman R; Sela BA; Karasik A; Vered I
Osteoporos Int; 2005 Dec; 16(12):1591-6. PubMed ID: 16362147
[TBL] [Abstract][Full Text] [Related]
18. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N
Clin Endocrinol (Oxf); 2001 Jun; 54(6):739-50. PubMed ID: 11422108
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.
Johnell O; Scheele WH; Lu Y; Reginster JY; Need AG; Seeman E
J Clin Endocrinol Metab; 2002 Mar; 87(3):985-92. PubMed ID: 11889149
[TBL] [Abstract][Full Text] [Related]
20. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally.
Gunczler P; Lanes R; Paz-Martinez V; Martins R; Esaa S; Colmenares V; Weisinger JR
J Pediatr Endocrinol Metab; 1998; 11(3):413-9. PubMed ID: 11517957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
